

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2021

Reference is made to the annual report of Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 March 2021 published on 27 July 2021 (the “**Annual Report**”). Capitalised terms used herein shall have the same meanings as those defined in the Annual Report unless the context requires otherwise.

In addition to the information disclosed in the Annual Report, the board of directors of the Company (the “**Board**”) would like to provide to the shareholders of the Company and the potential investors with the following supplementary information pursuant to paragraphs 26(2) and 32(4A)(a) and (b) of Appendix 16 to the Listing Rules.

RETIREMENT BENEFIT SCHEMES

In addition to the disclosure under note 12(c) on page 137 of the Annual Report, the Group had no forfeited contributions for the year ended 31 March 2021 (2020: nil) under these defined contribution retirement benefit schemes, in Hong Kong and the PRC, as contributions made by the Group were fully vested to the employees under the schemes.

FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

As disclosed in the Annual Report, the Company held financial assets at fair value through profit or loss of approximately HK\$466,322,000 as at 31 March 2021 which related to the convertible bonds issued by Innovative Pharmaceutical Biotech Limited (“**Innovative Pharm**”) the shares of which are listed on the Main Board of the Stock Exchange (stock code: 399).

Innovative Pharm is an investment holding company and its subsidiaries are principally engaged in the trading of beauty products and equipment, and research, development and commercialisation of the oral insulin product.

The respective fair values of the Company's investments in the convertible bonds issued by Innovative Pharm of HK\$466,322,000 and HK\$571,065,000 at 31 March 2021 and 2020 represented approximately 40.1% and 45.1% of the Group's total assets as at 31 March 2021 and 2020 respectively.

The above supplementary information does not affect the other information contained in the Annual Report.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 25 January 2022

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah, and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

* *For identification purpose only*